AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Zevin Asset Management LLC

Zevin Asset Management LLC lowered its stake in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 3.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 148,186 shares of the company's stock after selling 4,689 shares during the period. AstraZeneca accounts for 1.7% of Zevin Asset Management LLC's investment portfolio, making the stock its 27th largest position. Zevin Asset Management LLC's holdings in AstraZeneca were worth $10,892,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Banque Transatlantique SA acquired a new position in AstraZeneca during the 4th quarter worth about $26,000. Confluence Investment Management LLC acquired a new position in AstraZeneca during the 1st quarter worth about $27,000. Larson Financial Group LLC lifted its stake in AstraZeneca by 297.9% during the 1st quarter. Larson Financial Group LLC now owns 386 shares of the company's stock worth $28,000 after acquiring an additional 289 shares in the last quarter. Mascagni Wealth Management Inc. acquired a new position in AstraZeneca during the 4th quarter worth about $29,000. Finally, FNY Investment Advisers LLC acquired a new position in AstraZeneca during the 1st quarter worth about $29,000. Hedge funds and other institutional investors own 20.35% of the company's stock.

AstraZeneca Stock Up 2.4%

Shares of AZN traded up $1.64 during mid-day trading on Tuesday, reaching $70.36. The company's stock had a trading volume of 1,767,245 shares, compared to its average volume of 5,263,897. AstraZeneca PLC has a 12-month low of $61.24 and a 12-month high of $87.68. The stock has a market cap of $218.22 billion, a PE ratio of 28.26, a price-to-earnings-growth ratio of 1.26 and a beta of 0.37. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.90 and a quick ratio of 0.70. The company's 50 day moving average is $70.78 and its 200 day moving average is $70.99.

AstraZeneca (NASDAQ:AZN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, beating analysts' consensus estimates of $1.10 by $0.14. AstraZeneca had a return on equity of 33.14% and a net margin of 14.14%. The business had revenue of $13.59 billion for the quarter, compared to the consensus estimate of $13.71 billion. During the same quarter in the prior year, the business posted $2.06 EPS. The business's revenue for the quarter was up 7.2% on a year-over-year basis. Equities analysts anticipate that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on AZN shares. Berenberg Bank set a $97.00 price target on AstraZeneca in a report on Wednesday, July 9th. BNP Paribas started coverage on AstraZeneca in a report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price target on the stock. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $89.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.